GPC Biotech AG (GPCB)
Oncology Corporate Profile
- Products & Overview
- Recent News
HQ Location
101 College Road EastPrinceton, NJ 08540
Company Description
GPC Biotech AG is a publicly traded biopharmaceutical company focused on anticancer drugs. GPC Biotech's lead product candidate is satraplatin, an oral platinum compound. The Company has various anti-cancer programs in research and development that leverage its expertise in kinase inhibitors.
Website: http://www.gpc-biotech.com
Commercial Products
This company does not have any commercial productsPipeline Products
- Brand
- Generic
- Investigational
| Brand / Product | Class | Area of Study | Phase | Partnership |
|---|---|---|---|---|
| satraplatin | platinum chemotherapy agent (oral) | 2nd line metastatic Hormone refractory Prostate cancer (HRPC) (docetaxel refractory) | III | Agennix |
| talactoferrin | dendritic cell activator (DCA) | Locally advanced or metastatic Non Small Cell Lung Cancer (NSCLC) | III | Agennix / Spectrum |
| talactoferrin (+ sunitinib) | dendritic cell activator (DCA) | 1st line metastatic Renal cell carcinoma (RCC) | II | Agennix / Spectrum |
| satraplatin | platinum chemotherapy agent (oral) | Ovarian cancer | II | Agennix |
| satraplatin | platinum chemotherapy agent (oral) | Various cancer types | I | Agennix |
| talactoferrin | dendritic cell activator (DCA) | Various cancer types | I | Agennix / Spectrum |
| RGB-344064 | cyclin-dependent kinase inhibitor | Various cancer types | Preclinical | Agennix |
| RGB-286638 | kinase inhibitor | Various cancer types | Preclinical | Agennix |
View additional information on product candidates here »
Recent News Headlines
(Bloomberg) Aug 18, 2009 - GPC Biotech AG said its future may be in doubt if a planned merger with Agennix Inc. doesnt take place by the end of this year.
MARTINSRIED/MUNICH, Germany & PRINCETON, N.J.----GPC Biotech AG today reported that pre-clinical data on RGB-286638, the Company's multi-targeted protein kinase inhibitor, are being presented at the American Association for Cancer Research 100th Annual Meeting in Denver, Colorado.
(Bloomberg) Mar 25, 2009 - GPC Biotech AG, the German biotechnology company that agreed to combine with Agennix Inc. last month, aims to find a partner for the experimental talactoferrin cancer drug before cash runs out in 2010.
(GPC Biotech) Feb 18, 2009 - GPC Biotech AG and Agennix, Incorporated today announced that the two oncology-focused biotechnology companies have signed a Business Combination Agreement under which they propose to merge their businesses.
MARTINSRIED/MUNICH, Germany, & PRINCETON, N.J.----GPC Biotech AG today announced that enrollment has opened in a Phase 1 study evaluating RGB-286638 in patients with advanced solid tumors.
(StreetInsider.com) Dec 9, 2008 - GPC Biotech AG today announced that enrollment has opened in a Phase 1 study evaluating RGB-286638 in patients with advanced solid tumors.
MARTINSRIED/MUNICH, Germany & PRINCETON, N.J.----GPC Biotech AG today reported that new pre-clinical data on RGB-286638, the Companyâs multi-targeted protein kinase inhibitor, were presented at the 50th American Society of Hematology Annual Meeting in San Francisco, California in a poster entitled, âRGB-286638, a Novel Multi-Targeted Small Molecule Inhibitor, Induces Multiple Myeloma Cell Death through Abrogation of CDK-Dependent and Independent Survival Mechanismsâ .
MARTINSRIED, Germany & MUNICH, Germany & PRINCETON, N.J.----GPC Biotech AG today reported financial results for the third quarter and first nine months ended September 30, 2008.
MARTINSRIED/MUNICH, Germany & PRINCETON, N.J.----GPC Biotech AG today announced that the Company will hold a conference call on November 13, 2008 at 3 PM CET/9 AM ET to discuss its financial results for the third quarter of 2008 and provide a corporate update.
MARTINSRIED/MUNICH, Germany & PRINCETON, N.J.----GPC Biotech AG today announced that the Company will give a corporate presentation at the upcoming Rodman & Renshaw Annual Global Investment Conference in New York, NY.
MARTINSRIED/MUNICH, Germany & PRINCETON, N.J.----GPC Biotech AG today reported that pre-clinical data on RGB-286638, the Company's multi-targeted protein kinase inhibitor, were presented at the 20th EORTC-NCI-AACR Symposium: Molecular Targets and Cancer Therapeutics in Geneva, Switzerland in a poster entitled, "RGB-286638 is a novel multi-targeted protein kinase inhibitor with activity in chronic myelogenous leukemia models," .
(Forbes.com) Aug 7, 2008 - GPC Biotech AG. said its partner Celgene Corp. cancelled its development contract with the German biotech company over the experimental cancer drug satraplatin in Europe after an application for regulatory approval failed.
(Forbes.com) July 28, 2008 - GPC Biotech AG. said the company which has the marketing rights for its experimental cancer drug satraplatin withdrew its application for European approval for the treatment of prostate cancer, dashing what hopes remained for commercial use of the drug.